Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that
production of a proprietary GABA drug has started. Concurrently, the Scientific
and Medical Advisory Board is expanded with two leading experts in rheumatoid
arthritis and type 2 diabetes, Professor Daniel Furst, University of California,
Los Angeles (UCLA) and Associate Professor Michael Alvarsson, Clinic Director at
the Karolinska University Hospital.
Diamyd Medical has as previously reported broadened its operations to include
type 2 diabetes and rheumatoid arthritis with its own GABA drug. Development of
a GABA-drug product has now been launched in collaboration with a supplier of
GMP production and preclinical studies to determine the dose and formulation
start shortly.

To further strengthen its expertise in type 2 diabetes and rheumatoid arthritis,
Diamyd Medical has expanded its Scientific and Medical Advisory Board with two
new members, Professor Daniel Furst and Associate Professor Michael Alvarsson.

Daniel Furst, Professor at the University of California, Los Angeles (UCLA) and
rheumatologist, has published over 800 articles and 15 books, including 430
scientific publications, in his field. Doctor Furst’s research include clinical
pharmacology of anti-rheumatic drugs and the pathophysiology and treatment of
systemic sclerosis.

Michael Alvarsson is Senior Consultant Physician at the Department of
Endocrinology, Metabolism and Diabetes at Karolinska University Hospital and
Associate Professor at the Karolinska Institute, where he conducts clinical
diabetes research at the Department of Molecular Medicine and Surgery. Doctor
Alvarsson has long experience from clinical studies in type 2 diabetes as
principal investigator for numerous multinational clinical trials.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious
inflammatory diseases through pharmaceutical development and investments in stem
cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific
immunotherapy based on the exclusively licensed GAD-molecule. Six clinical
studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes
vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed
technology to develop a proprietary GABA drug product. Diamyd Medical is one of
the major shareholders in the stem cell company NextCell Pharma AB (former
Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion
Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc.,
Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the
ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
För ytterligare information, kontakta:
Ulf Hannelius, vd
Tel: +46 736 35 42 41.
E-post: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-post: info@diamyd.com Org. nr: 556242-3797 Hemsida: www.diamyd.com

Denna information är sådan information som Diamyd Medical är skyldigt att
offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades,
genom ovanstående kontaktpersons försorg, för offentliggörande den 1 november
2016 kl 08.30 CET